Sphera Funds Management LTD. reduced its stake in Kezar Life Sciences Inc (NASDAQ:KZR) by 7.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 212,000 shares of the company’s stock after selling 15,900 shares during the period. Sphera Funds Management LTD. owned 1.11% of Kezar Life Sciences worth $4,539,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of KZR. Laurion Capital Management LP acquired a new stake in Kezar Life Sciences during the 2nd quarter worth $173,000. BlackRock Inc. acquired a new stake in Kezar Life Sciences during the 2nd quarter worth $173,000. MYDA Advisors LLC acquired a new stake in Kezar Life Sciences during the 2nd quarter worth $213,000. Dean Capital Investments Management LLC acquired a new stake in Kezar Life Sciences during the 2nd quarter worth $585,000. Finally, Prosight Management LP acquired a new stake in Kezar Life Sciences during the 2nd quarter worth $721,000. Institutional investors and hedge funds own 47.40% of the company’s stock.
Separately, Zacks Investment Research downgraded Kezar Life Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. Five analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $27.33.
Shares of Kezar Life Sciences stock opened at $27.85 on Friday. Kezar Life Sciences Inc has a 12 month low of $14.77 and a 12 month high of $30.99.
Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.30) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.18. Equities research analysts predict that Kezar Life Sciences Inc will post -2.22 earnings per share for the current year.
WARNING: “Sphera Funds Management LTD. Sells 15,900 Shares of Kezar Life Sciences Inc (KZR)” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-sells-15900-shares-of-kezar-life-sciences-inc-kzr.html.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Further Reading: Can individual investors take part in an IPO?
Want to see what other hedge funds are holding KZR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kezar Life Sciences Inc (NASDAQ:KZR).
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.